文献速递真菌感染新发突发、热带与寄生虫病

念珠菌眼内炎与脉络膜视网膜炎的诊断与管理

Diagnosis and management of Candida endophthalmitis and chorioretinitis.
PubMed 文献 · Clin Microbiol Infect · 2025-05-27

本综述汇总念珠菌眼内炎(CE)及脉络膜视网膜炎在流行病学、诊断与治疗方面的现有证据。菌血症患者中CE患病率由棘白菌素前时代的1.8%升至棘白菌素应用后的2.1%。诊断主要依靠间接检眼镜检查,氟康唑与伏立康唑仍为一线全身治疗,玻璃体内注射与玻璃体切除术用于重症病例。

要点

  • 菌血症患者CE患病率由1.8%(棘白菌素前时代)升至2.1%(棘白菌素应用后)。
  • 间接检眼镜检查是视网膜可视化的参考标准,玻璃体液采样微生物确认虽为确诊依据但常受低菌量限制。
  • 氟康唑与伏立康唑为一线全身治疗,玻璃体内注射与玻璃体切除术保留用于重症病例。

核心结论

  • CE与脉络膜视网膜炎是菌血症少见但潜在破坏性的并发症,与视力丧失及长期疾病负担显著风险相关。
  • 有效管理依赖及时诊断与针对性抗真菌治疗,但不一致的指南、有限的证据及临床实践差异妨碍了诊疗路径。

研究设计与样本

  • 本综述为叙述性综述,检索PubMed、Embase与Scopus,聚焦流行病学、发病机制、诊断、治疗与结局。
  • 文中复习了美国感染病学会、欧洲医学真菌学联盟与美国眼科学会的指南。

主要发现

  • 菌血症患者中CE患病率由棘白菌素前时代的1.8%升至棘白菌素应用后的2.1%。
  • 诊断主要依靠间接检眼镜检查,其为视网膜可视化的参考标准;部分病例中光学相干断层扫描或眼底照相可辅助病灶评估。
  • 经玻璃体液采样的微生物学确认仍为确诊依据,但常受低病原体负荷限制。
  • 基于成簇规律间隔短回文重复序列的真菌DNA检测等新兴诊断显示出应用前景。
  • 人工智能辅助影像工具已在其他视网膜疾病中确立,但尚未在念珠菌眼部感染中得到验证。

关键数值与推荐

  • CE患病率:棘白菌素前时代1.8%,棘白菌素应用后2.1%。
  • 氟康唑与伏立康唑仍为一线全身治疗;玻璃体内注射与玻璃体切除术保留用于重症病例。
  • 间接检眼镜检查为视网膜可视化的参考标准。
  • 微生物学确认通过玻璃体液采样,仍为确诊依据。

临床怎么用

  • CE管理改善需要统一的筛查方案、及时的 ophthalmologic 诊疗可及性及多学科协作。
  • 临床应关注间接检眼镜检查作为视网膜可视化参考标准的作用,并在部分病例辅以光学相干断层扫描或眼底照相。
  • 氟康唑与伏立康唑作为一线全身治疗,玻璃体内注射与玻璃体切除术用于重症病例。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Candida endophthalmitis (CE) and chorioretinitis are uncommon but potentially devastating complications of candidemia, associated with significant risks of vision loss and long-term morbidity. Effective management relies on timely diagnosis and targeted antifungal therapy. However, diagnostic and therapeutic approaches are hindered by inconsistent guidelines, limited evidence, and variations in clinical practice. OBJECTIVES: This review synthesizes current knowledge on CE and chorioretinitis to provide a comprehensive framework for clinicians. It addresses diagnostic challenges, including ophthalmoscopy, imaging, and microbiological diagnostics, and therapeutic strategies such as systemic and intravitreal antifungal therapies, surgical interventions, and serial ophthalmic evaluations. SOURCES: An extensive literature search was conducted using PubMed, Embase, and Scopus, with a focus on epidemiology, pathogenesis, diagnostics, treatment, and outcomes. Guidelines from the Infectious Diseases Society of America, European Confederation for Medical Mycology, and American Academy of Ophthalmology were reviewed. CONTENT: The prevalence of CE among patients with candidemia has increased from 1.8% in the pre-echinocandin era to 2.1% after the introduction of echinocandins. Diagnosis relies primarily on indirect ophthalmoscopy, the reference standard for retinal visualization. In selected cases, optical coherence tomography or fundus photography may support lesion assessment. Microbiological confirmation via vitreous sampling remains definitive but is often limited by low organism burden. Emerging diagnostics-such as clustered regularly interspaced short palindromic repeats-based fungal DNA assays-have shown promise. Although artificial intelligence-assisted imaging tools are established in other retinal diseases, they have not yet been validated for Candida ocular infections. Fluconazole and voriconazole remain first-line systemic therapies, with intravitreal injections and vitrectomy reserved for severe cases. IMPLICATIONS: Improving outcomes in CE requires harmonized screening protocols, timely access to ophthalmologic care, and multidisciplinary collaboration. Future research should aim to refine diagnostic algorithms, define optimal treatment durations, clarify the role of emerging diagnostics, and leverage telemedicine and imaging technologies to improve early detection and longitudinal monitoring.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Permpalung N, Sedik S, Pappas PG, et al. Diagnosis and management of Candida endophthalmitis and chorioretinitis. Clin Microbiol Infect. 2025. PMID: 40441350. doi:10.1016/j.cmi.2025.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。